



XX claim 20; Page 36; 42pp; English.

PS The receptor is a novel active site in human ezrin. Ezrin regulates the structure of the cortical cytoskeleton to control cell surface topography. The present invention relates to peptides (see AAB82261 to AAB82041) that bind to heparin with greater affinity than HEP1 (see AAB82046). The heparin receptor binding peptides are useful for inducing immune response, and for treating infectious diseases, cancer and HIV-related dementia. The present peptide binds to domains A and B of the heparin receptor (AAH82019 and AAH82020).

XX Sequence 14 AA:

Query Match 100.0%; Score 69; DB 22; Length 14;

Best Local Similarity 100.0%; Pred. No. 0.00073;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SQ Query 1 EREKQMMREKEEL 14

DB 184 EREKQMMREKEEL 197

---

XX and AAB7789 represent sequences used in the exemplification of the present invention.

CC New pages not to be filed and Page 7953 of the sequence listing were missing at time of publication, meaning no sequences are present for SEQ ID NO:10227 to 1052, 7921 and 7922.

CC Sequence 436 AA;

Query Match 100.0%; Score 69; DB 22; Length 46;

Best Local Similarity 100.0%; Pred. No. 0.024;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC Sequence 1 EREKQMMREKEEL 14

DB 184 EREKQMMREKEEL 197

---

XX RESULT 3

ANY27443 standard; protein; 586 AA.

XX ID ANY27443

XX AC ANY27443;

XX DT 26-NOV-1999 (first entry)

XX DE Amino acid sequence of human ezrin polypeptide.

XX KW Pharmaceutical; ezrin; mutant; tumor; metastasis; human.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT Misc difference 354

XX /note\* "the TYR at this position can be mutated (preferably to a Phe) to construct an ezrin mutant of the invention."

XX FT

XX PN WO9947150-A2.

XX PID 23-SEP-1999.

XX PF 18-MAR-1999; q9W0-EPO2054.

XX PR 18-MAR-1998; qRTS-0046725

XX PA (CIRI-) INST CURIE.

XX PA (CNRS ) CNRS CENT NAT RECH SCI.

XX PI Arpin M, Crepaldi T, Gautreau A, Louvard D;

XX DR WPI; 1999-561851/47.

XX PT New composition for prevention and treatment of tumors and metastasis

XX PS Example 1; Fig 1; 31pp; English.

XX The invention provides a pharmaceutical composition containing c77 in protein, RNA or DNA mutated on tyrosine 353, or a functional fragment or derivative of the ezrin mutant. The new composition is useful for prevention and/or treatment of tumors, and especially metastasis. The present sequence represents the amino acid sequence of human ezrin (before the maturation by deletion of the first amino acid Met).

XX Sequence 586 AA;

Query Match 100.0%; Score 69; DB 20; Length 586;

Best Local Similarity 100.0%; Pred. No. 0.033;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC Sequence 1 EREKQMMREKEEL 14

DB 384 EREKQMMREKEEL 347

---



KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder.  
 XX  
 XX OS Homo sapiens.  
 XX PN WO200175067-A2.  
 XX PD 11-OCT-2001.  
 XX PF 30-MAR-2001: 2001WO-US00631.  
 XX PR 31-MAR-2000: 2000US0548217.  
 XX PR 23-NOV-2003: 2003US0649167.  
 XX PA (HYSE-) HYSEQ INC.  
 PA Dumanac RT, Liu C, Tang YT;  
 XX DR WPI: 2001-639362/73.  
 XX DR N-PDB: AAS84134.  
 XX DR: 2001-639362/73.  
 XX DR-N-PDB: AAS80764.  
 XX PT New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity.  
 XX PS Claim 20: SEQ ID No 50306: 103pp; English.  
 XX The invention relates to isolated polynucleotide (I) and  
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 CC and gene mapping, and in recombinant production of (II). The  
 CC polynucleotides are also used in diagnostics as expressed sequence tags  
 CC for identifying expressed genes. (II) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC identifying expressed genes. (II) is useful in gene therapy techniques  
 CC to restore normal activity of (II) or to treat disease states involving  
 CC identifying antibodies against it, detecting or  
 CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 CC a food supplement. (II) and its binding partners are useful in medical  
 CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 CC disorders involving aberrant protein expression or biological activity.  
 CC The polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. ABG00010-ABG3037 represent novel human  
 CC diagnostic amino acid sequences of the invention.  
 CC Note: The sequence data for this patent did not appear in the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at [http://wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences).  
 XX Sequence 503 AA;  
 SO Query Match 73.9%; Score 51; DB 22; Length 593;  
 SO Best Local Similarity 71.4%; Pred. No. 13;  
 SO Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
 SO YY 1 EREKEMMREKEEL 14  
 SO 1:|||||:|||||||  
 SO 1b 254 EKEKEMMREKEEL 267  
 SO RESULT 7  
 ABG1947 ID ABG1947 standard; Protein: 593 AA.  
 XX AC ABG1947;  
 XX DT 18-FEB-2002 (first entry)  
 XX DE Novel human secreted protein #3551.  
 XX KW Human; vaccination; gene therapy; nutritional supplement;  
 KW stem cell proliferation; haemopoiesis; nerve tissue regeneration;  
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.  
 XX

OS Homo sapiens.  
 XX  
 PN WO200179449-A2.  
 XX  
 DE 25-OCT-2001.  
 PD  
 XX  
 IP 16-APR-2001; 2001W02500949-C.  
 XX  
 PR 18-APP-2000; 2000US05629799.  
 PR 26-JAN-2001; 2001US05629799.  
 PA  
 XX  
 (HYSE-7) HYSEQ INC.  
 XX  
 P1 Tang YH, Liu C, Pramanac RT;  
 XX  
 DP 2001-6-17; 5,770  
 PT Nucleic acids encoding a range of human polypeptides, useful in genetic  
 vaccination, testing and therapy -  
 XX  
 PS claim 20; Page 742; 76 ref; English  
 XX  
 The invention relates to novel human secreted polypeptides. The  
 polypeptides and antibodies to the polypeptides are useful for  
 determining the presence of or predisposition to a disease associated with altered levels of polypeptide. The polypeptides are also useful for  
 identifying agents (agonists and antagonists) that bind to them. Cells  
 expressing the proteins are useful for identifying a therapeutic agent  
 for use in treatment of a pathology related to abnormal expression or  
 physiological interactions of the polypeptide. Vectors comprising  
 the nucleic acids encoding the polypeptides and cells genetically  
 engineered to express them are also useful for producing the proteins.  
 The proteins are useful in genetic vaccination, testing and  
 can be used as nutritional supplements. They may be used to  
 increase stem cell proliferation; to regulate haemopoiesis; and in  
 bone, cartilage, tendon and/or nerve tissue growth or regeneration,  
 immune suppression and/or stimulation; as anti-inflammatory agents, and  
 in treatment of leukaemias. AAU16454 and AAU16455 represent  
 sequences of novel human secreted proteins of the invention.  
 Sequence 52 AA:  
 Query Match 99% Score 49; IR 22; Tcfrag: 52;  
 Best Local Similarity 100%; Pred No 2/2;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0.  
 5 EMMMPEREL 14  
 11111111  
 6 EMMMPEREL 15  
 XX  
 RESULT 9  
 AAU16454  
 ID AAU16454 standard; protein; 357 AA.  
 XX  
 AC  
 DE Human novel secreted protein, Seq ID: 14C7.  
 DT 07-NOV-2001 (first entry)  
 XX  
 KW Human, immunosuppressive, antiarthritis, antirheumatic,  
 cytostatic, cardiotonic, astringent, aperientive, neurotropic,  
 neurotrophic, antihypertensive, astringent, aperientive, mucolytic,  
 vulnerary; secreted protein, membrane-associated protein,  
 fibroblast, epithelial, discoid, endo-epithelial, connective tissue,  
 connective tissue disorder, connective tissue disease, angiogenesis,  
 nervous system disorder, Alzheimer's disease, antigen, cellular disorder,  
 corneal infection, wound healing, epithelial cell proliferation,  
 skin ageing; food additive; preservative; antiproliferative.  
 XX  
 OS Homo sapiens.

WPID: 2001-488783/53 NPSPDB, AAS26441.	New nucleic acid mo- difications, prevent used as food additive	Claim 11: SEQ ID No The invention relates to modified starches related to prevent, treat or di- agnose, e.g., heart disease, rheumatoid arthritis, hyper- cholesterolemia, cardio- vascular disease, e.g., cere- bral vascular disease, Alzheimer's disease, and ocular disorders. The disorders listed in the claims can be used to prevent skin aging, e.g., transplantation, for regenerative tissues such as a food additive, cap- abilities, fat com- ponents, minerals, cofactors and sequence represents sequence represents	1 EBEKEMMPEKEEL 149 QPKKGQDQKQHQH LT 10 6019 AATTC19 standard, E AAU16019; 07 NOV 2001 (first Human novel secreted Human; immunostimulus cytostatic, cardiotonic neuroprotective, anti- vulgarly; secreted hyperplastulatory; c cerebrovascular disor nervous system disorder coronary infection; w skin aging; food as Homo sapiens. W02001532-A2. 02-AUG-2001. 17-JAN-2001; 2001WO 31-JAN-2000; 2000US
---	---	---	---

encoded 461 human secreted proteins for  
existing or anticipated medical conditions and  
preservatives -

380pp: English.

Isolated nucleic acid molecules and their  
polypeptides and proteins are used to  
treat a medical condition in e.g., humans, mice,  
dogs, chickens or sheep. They  
are pathological conditions of susceptibility  
to antibodies to the proteins can also  
be associated with the disorders and in  
certain diseases or organs linked  
to disorders which are diagnosed or treated  
e.g., rheumatoid arthritis,  
as a neoplasia of the breast or liver,  
cardiac arrest, cerebrovascular disorders e.g.,  
angiogenesis, nervous system disorders e.g.,  
infections caused by bacteria, viruses and fungi  
and many other  
specification, the polypeptides can also  
be used epithelial cell proliferation, to  
maintain organs before  
removal, to maintain cell culture of primary tissues, to  
increase or decrease storage  
lipid, protein, carbohydrate, vitamins,  
nutritional components, the present  
secreted protein of the invention.

Score: 477, IP: 22; Length: 357;

4	Mismatches	2	Indels	0	Gaps
4	Prod. No.	302			

: 472 AA.  
In, Seq ID 972.

antiarthritic, antihematitic,  
nootropic, cerebroprotective, nootropic;  
viticide, fungicide, ophthalmological;  
hematoid arthritis;  
cardiovascular disorder, cardiac arrest;  
ischaemia; angiogenesis;  
Behceter's disease, infection, ocular disorder  
including, epithelial cell proliferation;  
preservative, antiflitterative.



PR	30-MAR-2000;	2000US0540763.
PS	Claim 11; SEQ ID No 972; 980pp; English.	XX
XX	The invention relates to isolated nucleic acid molecules and their encoded secreted proteins. The nucleic acids and proteins are used to prevent, treat or ameliorate a medical condition in e.g. humans, mice, rabbits, goats, horses, rats, dogs, chickens or sheep. They are also used in diagnosing a pathological condition or susceptibility to a pathological condition. Antibodies to the proteins can also be used in alleviating symptoms associated with the disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays (ELISA). Disorders which are diagnosed or treated include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. neoplasias of the breast or liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g. Alzheimer's disease, infections caused by bacteria, viruses and fungi and ocular disorders e.g. corneal infection, and many other disorders listed in the specification. The polypeptides can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to regenerate tissues and in chemotherapy. The peptides can also be used as a food additive or preservative to increase in decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors and other nutritional components. The present sequence represents a novel secreted protein of the invention.	XX
Query Match	Score 47, DB 22, Length 472, Best Local Similarity 57.1%, Pred. No. 40;	XX
Matches	R: conservative 4; Mismatches 2; Gaps 0.	XX
QY	1 EREKEQMREKEEL 14	XX
Db	188 QKEREQLOQEKEQEL 201	XX
RESULT 11	AAB42228	XX
ID	AAB42228 standard; Protein, 484 AA.	XX
AC	AAB42228	XX
XX	08-FEB-2001 (first entry)	XX
DE	Human ORF OPFL1992 polypeptide sequence SEQ ID NO 3984.	XX
KW	Human; open reading frame; ORF; detection, cytostatic; hepatotoxic; neurotoxic; antipsoriasis; osteopathic; antiarthritic; immunosuppressant; neuroprotective; anticonvulsant; antidiabetic; coagulant; antihypertensive; thrombolytic; vasotropic; immunosuppressive; antidiabetic; antiviral; antifungal; antiallergic; aplastic anaemia; burns, wounds, bone and cartilage damage; nocturnal haemoglobinuria; antiinflammatory disease; coagulation; antithrombotic; contraceptive; antidiabetic; antihypertensive; graft vs host disease; cardiovascular disease; diabetes mellitus; cholesterol ester storage disease; lupus erythematosus; infection; allergic; aplastic anaemia; nocturnal haemoglobinuria; bone damage; cartilage damage; contraceptive.	XX
KW	antianemic; gene therapy; cancer; proliferative disorder; hypertension; neurodegenerative disease; osteoporosis; graft vs host disease; graft vs host disease; diabetes mellitus; hypothyroidism; SCID; AIDS; cholesterolemia; immunosuppressant; cytostatic; gene therapy; cancer; severe combined immunodeficiency; malacia; autoimmune disorder; asthma; allergic; aplastic anaemia; nocturnal haemoglobinuria; bone damage; cartilage damage; contraceptive.	XX
KW	Homo sapiens	XX
PN	W020005847-A2.	OS
XX	05-OCT-2000.	XX
PD	2000WO-US08621.	PN
PF	31-MAR-2000; 2000WO-US08621.	XX
XX	9901S-0127607.	XX
PR	31-MAR-1999; 9901S-0127607.	XX
PR	02-APR-1999; 4401S-0127607.	XX
PR	05-APR-1999; 9901S-0127607.	XX
PT	Novel nucleic acids and peptides derived from open reading frames X, PT used for treating e.g. cancer, proliferative disorders, neurodegenerative disorders and cardiovascular disease -	XX
FT	Claim 11; Page 315-3152; 5507pp, English.	XX
XX	AM274446 to AAC77605 encode the proteins given in AAB40237 to AAB43397, which represent the human ORFX open reading frames 1 to 3161. The ORFX sequences have activities such as, cytostatic, neurotropic; hepatotoxic; antipsoriatic; antiparkinsonian; neurotropic; neuroprotective; osteopathic; anticonvulsant; autonomic; thrombolytic; coagulant; vasotropic; immunostimulant; coagulant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive; dermatological; immunosuppressive; antiinflammatory; antiviral; antidiabetic; antihypertensive; antithrombotic; antithyroid; and antianemic. The sequences can be used for determining the presence of or predisposition to, or preventing or treating ORFX-associated disorder. The proteins and nucleic acids may be used to treat cancers, proliferative disorders, neurodegenerative disorders, osteoarthritis, graft vs host disease, cardiovascular disease, systemic lupus erythematosus, severe combined immunodeficiency (SCID), AIDS, viral, bacterial or fungal infection, malaria, autoimmune disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and cartilage damage; coagulation, to inhibit thrombosis; and as a contraceptive.	XX
Sequence	484 AA;	XX
Query	Match 68.1%; Score 47, DB 21; Length 484;	XX
XX	Best Local Similarity 57.1%; Pred. No. 41;	XX
Matches	8; Conservative 4, Mismatches 2, Gaps 0;	XX
QY	1 EREKEQMREKEEL 14	XX
DB	276 QKEREQLOQEKEQEL 289	XX
RESULT 12	RES012	XX
ID	AAM42158	XX
AC	AAM42158 standard; Protein, 580 AA.	XX
XX	22-OC1-2091 (first entry)	XX
DE	Human polypeptide SEQ ID NO 7089.	XX
KW	Human peripheral nervous system; neuropathy; central nervous system; CNS; Alzheimer's; parkinson's disease; Huntington's disease; haemostatic; amphotropic lateral sclerosis; Shy-Drager Syndrome; chemotactic; chemokinetic; thrombolytic; drug screening; arthritis; inflammation; leukaemia.	XX
KW	Homo sapiens	XX
XX	Hom sapiens	XX
XX	WO20015312-A1.	XX
XX	26-JUL-2001.	XX
XX	26-DEC-2000; 2000WO-US34263.	XX

21 JAN 2000; 2000019-0488725  
 25 APR 2000; 2000018-0573737  
 09 JUL 2000; 2000018-0573842  
 19 JUL 2000; 2000018-0573842  
 14 AUG 2000; 2000018-0573842  
 14 SEP 2000; 2000018-0562191  
 19 OCT 2000; 2000018-0593036  
 29 NOV 2000; 2000018-0593036  
 XX  
 PA (HYSE-) HYSEQ INC.  
 PA Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang J, Wang J, Wang J, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
 PA Zhou P, Goodrich R, Drmanac RT;  
 WPI: 2001-442253/47  
 N-PSDB: AAI13134.  
 XX  
 Novel nucleic acids and pharmaceutical compositions, as well as methods for their use, for the treatment of peripheral nervous system injuries, such as central nervous system injuries.  
 XX  
 Example 2: SHC 1D NC 7089; 1C078pp, Engl. ist.,  
 XX  
 The invention relates to human nucleic acids (AA157798-AA161369) and the encoded polypeptides (AM3642-AM4213) with anti-inflammatory, immunosuppressant and cytostatic activity. The polynucleotides are useful in gene therapy. A composition containing a polypeptide or polynucleotide of the invention may be used to treat diseases of the peripheral nervous system, such as peripheral nervous injuries, peripheral neuropathy, such as localised neuropathies and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and shy drager syndrome, other uses include the utilisation of the activities such as: immune system suppression, Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombotic activity, cancer diagnosis and therapy, drug screen assays for receptor activity, arthritis and inflammation, leukaemias C.N.S disorders  
 Note: The sequence data for this patent did not form part of the prior specification.

SO	Sequence	580 AA.	Score	47:	DB 22:	Length	580;
Query Match			68.1%				
Best Local Similarity			57.1%				
Matches	8	Conservative		4	Mismatches	2:	indels
QY	1 ERKEKOMMREKEFEL 14						
DB	4.95 OKKEKDIOFFKEFEL 508						

*Homo sapiens* WO200153312-A1.  
XXX OS PN XXX PPD 26-JUL-2001  
XXX PN XXX PPD 26-JUL-2001

ISQ	Sequence	580 AA:	Query Match	68.1%	Score 47;	DB 22;	Length 580;
			Best Local Similarity	57.1%	Pred. No. 50;		
			Matches	8;	Conservative	4;	Mismatches
						2;	Indels
						0;	Gaps
QY		1 EREKEQMREKEEL 14					
QDB	4.95	QKEKFQHQEFQEL 508					

XX  
PR 29-JUL-1999; 99JP-024B036.  
PR 27-AUG-1999; 99JP-030053.  
PR 11-JAN-2000; 2000JP-0118776.  
PR 02-MAY-2000; 2000JP-018367.  
PR 09-JUN-2000; 2000JP-0241949.  
XX  
PA (HHL-I) HELIX RES. NSI.  
XX  
P1 otata T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto T,  
Ishii S, Sugiyama T, Wakamatsu A, Narai K, Matsuki T.  
XX  
DR WPI; 2001-318704/04  
XX  
PT Primer sets for synthesising polypeptides, particularly the  $\alpha$ -SII  
full-length cDNAs defined in the specification, and for the detection  
and/or diagnosis of the abnormality of the proteins encoded by the  
full-length cDNAs.  
XX  
DS claim 8; SEQ ID 18294; 2537pp + Cl ROM; End fish.  
XX  
CC The present invention describes primer sets for synthesising 5602  
CC full-length cDNAs defined in the specification where a primer set  
CC comprises: (a) an oligonucleotide comprising a sequence complementary  
CC to the complementary strand of a polynucleotide which comprises one of  
CC the 5602 nucleotide sequences defined in the specification, where the  
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination  
CC of an oligonucleotide comprising a sequence complementary to the  
CC complementary strand of a polynucleotide which comprises a 5' end  
CC sequence and an oligonucleotide comprising a sequence complementary to a  
CC polymeric carboxylic conjugate's 3'-end sequence, where the  
CC the 5'-end sequence is selected from those defined in  
CC the specification. The primer sets can be used in antisense therapy and  
CC in gene therapy. The primers are useful for synthesising polynucleotides,  
CC particularly full-length cDNAs, the primers are also useful for  
CC detection and/or diagnosis of the abnormality of the proteins encoded by  
CC the full-length cDNAs. The primers allow obtaining of the full-length  
CC cDNAs easily without any sterilised methods. AAI1363 to AAII1368 and  
CC AAB1874 to AAB1874 represent human cDNA sequences; AAB92446 to  
CC AAB95833 represent human amino acid sequences; and AAII1629 to AAII1632  
CC represent oligonucleotides, all of which are used in the exemplification  
CC of the present invention.  
XX  
Sequence 690 AA:  
Query Match 66.1%; Score 47; DB 22; Length 690;  
Best Local Similarity 57.1%; Pred. No. 59;  
Matches 8; conservative 4; Mismatches 2; Indels 0; Caps 0;  
Seq Sequence 691 AA:  
Query Match 68.1%; Score 47; DB 22; Length 691;  
Best Local Similarity 57.1%; Pred. No. 59;  
Matches 8; conservative 4; Mismatches 2; Indels 0; Caps 0;  
QY 1 EREKOMMREKEEL 14  
Db 483 QKEKEQLEKEQEL 496  
RESULT 15  
ID AAM4072  
ID AAM40372 standard: Protein: 691 AA.  
XX  
AV AAM40372;  
XX  
D1 22 OCT-2001 (first entry)  
DE Human polypeptide SEQ ID No 3517.  
XX  
Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;  
KW peripheral nervous system; neuropathy; central nervous system; CNS;  
KW Alzheimer's; Parkinson's disease; Huntington's disease, haemostatic;  
KW amyotrophic lateral sclerosis; Shy Drager syndrome; chemoattractant;  
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
KW leukaemia.  
XX Homo sapiens.